Inhibition of coronary restenosis by antithrombin III in atherosclerotic swine

Coronary Artery Disease

Volumn 7, Issue 11, 1996, Pages 851-861

  Ali, M Nadir ^a,b   Mazur, Wojciech ^a   Kleiman, Neal S ^a   Rodgers, George P ^a   Abukhalil, John M ^a   French, Brent A ^a   Raizner, Albert E ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

animal model; antithrombin III; restenosis

Indexed keywords

ANTITHROMBIN III; HEPARIN;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BALLOON DILATATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MORPHOMETRICS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RESTENOSIS; STENT; SWINE;

EID: 0030463803     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199611000-00010     Document Type: Article

References (57)

1. Forrester JS, Fishbein M, Helfant R, Fagin J: A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991, 17:758-769.
2. Wilcox JN: Thrombin and other potential mechanisms underlying restenosis. Circulation 1991, 84:432-435.
3. Yu TH, Hung DT, Wheaton VI, Coughlin SR: The molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64:1057-1068.
4. McNamara CA, Sarembock IJ, Gimple LW, Coughlin SR, Owens GK: Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993, 91:94-98.
5. Graham DJ, Alexander JJ: The effects of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg 1990, 11:307-313.
6. Harlan JM, Thompson PJ, Ross RR, Bowen-Pope DF: Thrombin induces release of platelet-derived growth factor-like molecule(s) by cultured human endothelial cells. J Cell Biol 1986, 103:1129-1133.
7. Okazaki H, Majesky MW, Harker LA, Schwartz SM: Regulation of platelet-derived growth factor ligand and receptor gene expression by a-thrombin in vascular smooth muscle cells. Circ Res 1992, 71:1285-1293.
8. Jones A, Greczy CL: Thrombin and factor Xa enhance the production of interleukin-1. Immunology 1990, 71:236-241.
9. Libby P, Warner SJ, Friedman GB: Interleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of growth factor inhibitory prostanoids. J Clin Invest 1988, 88:187-198.
10. Schwartz RS, Holmes DR, Topol EJ: The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992, 20:1284-1293.
11. Steele PM, Chesebro JH, Stanson AW, Fuster V: Balloon angioplasty, Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985, 57:105-112.
12. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC: Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991, 84:232-243.
13. Zoldhelyi P, Bichler J, Owen WG, McBane RM, Hassinger N, Gaspar D, Chesebro JH: Measurement of thrombin-hirudin complex documents persistent thrombin formation in patients with unstable angina during anticoagulation with recombinant hirudin [abstract]. Circulation 1993, 88 (suppl I):I-319A
14. Bos A, Deckers JW, Heyndrickx GR, Laarman G-J, Suryapranata H, Zijlstra F, Close P, et al.: Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993, 88:2058-2066.
15. Lidon R-M, Theroux P, Juneau M, Adelman B, Maraganore J: Initial experience with a direct antithrombin, hirulog in unstable angina: anticoagulant, antithrombotic and clinical effects. Circulation 1993, 88:1495-1501.
16. Gold HK, Torres FW, Garabedian HD, Werner W, Jang I, Khan A, et al.: Evidence of a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039-1047.
17. Gasic GP, Arenas CP, Gasic TB, Gasic GJ: Coagulation factors X, Xa and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992, 89:2317-2320.
18. Beresford CH, Owen MC: Minireview - antithrombin III. Int J Biochem 1990, 22:121-128.
19. Hedin U, Frebelius S, Sanchez J, Dryjski M, Swedenborg J: Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. Arterioscler Thromb 1994, 14:254-260.
20. Rosenberg RD: Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989, 87 (suppl 3B):2S-9S.
21. Hatton MW, Moar SL, Richardson M: Evidence that rabbit 1251-AT III binds to proteoheparan sulfate at the subendothelium of the rabbit aorta in vitro. Blood Vessels 1988, 25:12-27.
22. Nydahl S, Frebelius S, Swedenborg J: Inhibition of thrombin on subendothelium. Eur J Surg Res 1989, 21:287-295.
23. Pasche B, Swedenborg J, Hedin U, Olson P, Ljungqvist A: Thrombin inhibitory capacity of the injured vessel wall. Thromb Res 1991, 62:531-544.
24. Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA: The antithrombin III study group. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989, 87:53S-60S.
25. Rodgers GP, Minor ST, Robinson K, Cromeens D, Woolbert SC, Stephens LC, et al.: Adjuvant therapy for intracoronary stents: investigations in atherosclerotic swine. Circulation 1990, 82:560-569.
26. Rodgers GP, Minor ST, Robinson K, Cromeens D, Stephens LC, Woolbert SC, et al.: The coronary artery response to balloon-expandable flexible stent in the aspirin and non-aspirin treated swine model. Am Heart J 1991, 122:640-647.
27. Karas SP, Gravanis MB, Santoian EC, Robinson KA, Anderberg KA, King SB: Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992, 20:467-474.
28. Schwartz RS, Murphy JG, Edwards WD Camrud AR, Vlietstra R, Holmes DR: Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation 1990, 82:2190-2200.
29. Grinstead WC, Rodgers GP, Mazur W, French BA, Cromeens DM, Van Pelt C, et al.: Comparison of three porcine restenosis models: the relative importance of hypercholesterolemia, endothelial abrasion, and stenting. Coronary Artery Dis 1994, 5:425-434.
30. Tollefsen DM: Laboratory diagnosis of antithrombin and heparin cofactor II deficiency. Semin Thromb Hemost 1990, 16:162-168.
31. Reiber JHC, Serruys PW, Kooijman CJ: Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 1985, 71:280-288.
32. Carney DH, Redin W, McCroskey L: Role of high-affinity thrombin receptors in postclotting cellular effects of thrombin. Semin Thromb Hemost 1992, 18:91-103.
33. Kanthou C, Parray G, Wijelath E, Kakkar VV, Demoliouj-Mason C: Thrombin-induced proliferation and expression of platelet-derived growth factor A-chains gene in human vascular smooth muscle cells. FEBS Lett 1992, 314:143-148.
34. Nelken NA, Soifer SJ, O'Keefe J, Vu T-KD, Charo IF, Coughlin SR: Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992, 90:1614-1621.
35. Muller DW, Ellis SG, Topol EJ: Experimental models of coronary artery restenosis. J Am Coll Cardiol 1992, 19:418-432.
36. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S, et al.: Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 1993, 21:249-254.
37. Heras M, Chesebro JH, Webster MW, Mruk JS, Grill DE, Penny WJ, et al.: Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990, 82:1476-1484.
38. Heras M, Chesebro JH, Penny WJ, Bailey KR, Lam J, Holmes DR, et al.: Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988, 78:654-660.
39. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V: Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 1989, 79:657-665.
40. Ragosta M, Gimple LW, Gertz SD, Dunwiddie CT, Vlasuk GP, Haber HL, et al.: Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1994, 89:1262-1271.
41. Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, et al.: Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994, 90:2671-2678.
42. Hatton MW, Moar SL, Richardson M: Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989, 135:499-508.
43. Frebelius S, Nydahl S, Swedenborg J: Coagulant and noncoagulant thrombin enzymatic activity on the endothelium. Blood Coag Fibrinol 1990, 1:287-295.
44. Frebelius S, Hedin U, Swedenborg J: Thrombogenicity of the injured vessel wall. Role of antithrombin and heparin. Thromb Haemost 1994, 71:147-153.
45. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
46. Bar-Shavit R, Eldor A, Vlodavsky I: Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J Clin Invest 1989, 84:1096-1104.
47. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Mirulog Angioplasty Study Investigators. N Engl J Med 1995, 333:764-769
48. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ. et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995, 333:757-763.
49. Marciniak E, Gockerman JP: Heparin-induced decrease in circulating antithrombin-III. Lancet 1977, ii:581-584.
50. Pizzo SV: Serpin receptor I: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am J Med 1989, 87(suppl 3B):10S-14S.
51. Miller J, Granger C, Bovill E, Krucof M, Berrios E, Harrington R, et al.: Rebound increase in thrombin activity after cessation of intravenous heparin [abstract]. Circulation 1993, 88:I-202A.
52. Theroux P, Waters D, Lam J, Juneau M, McCans J: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145.
53. Edelman ER, Karnovsky MJ: Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 1994, 89:770-776.
54. Ellis SG, Roubin GS, Wilentz J, Lin S, Douglas JS, King SB: Effect of 18-to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989, 117:777-782.
55. Lehmann K, Dona RJ, Feuer JM, Hall PX, Hoang DT: Paradoxical increase in restenosis rate with chronic heparin use. Final results of a randomized trial [abstract]. J Am Coll Cardiol 1991, 17:181A.
56. Urban P, Buller N, Fox K, Shapiro L, Bayliss J, Rickards A: Lack of effect of warfarin on the restenosis rate or on clinical outcome after balloon coronary angioplasty. Br Heart J 1988, 60:485-488.
57. Thornton MA, Gruentzig AR, Hollman J, King SB, Douglas JS: Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984, 69:721-727.